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Background: The inability to quantify sexual exposure to HIV limits
the power of HIV prevention trials of vaccines, microbicides, and preexposure
prophylaxis in women. We investigated the detection of HIV-1 and Y
chromosomal (Yc) DNA in vaginal swabs from 83 participants in the
HPTN 035 microbicide trial as biomarkers of HIV exposure and unpro-
tected sexual activity.
Methods: One hundred forty-three vaginal swabs from 85 women were
evaluated for the presence of Yc DNA (Quantifiler Duo DNA quantifica-
tion kit; Applied Biosystems) and total HIV-1 DNA (single-copy in-house
quantitative polymerase chain reaction assay). Y DNA detection was paired
with self-reported behavioral data with regard to recent coitus (e1 week
before collection) and condom usage (100% vs. G100% compliance).
Results: Yc DNAwas detected in 62 (43%) of 143 swabs. For the 126
visits at which both behavioral data and swabs were collected, Yc DNA
was significantly more frequent in women reporting less than 100% con-
dom usage (odds ratio, 10.69; 95% confidence interval, 2.27Y50.32;
P = 0.003). Notably, 27 (33%) of 83 swabs from women reporting 100%
condom usage were positive for Yc DNA. HIV DNAwas only detected in
swabs collected postseroconversion.
Conclusions: The use of Yc DNA in HIV prevention trials could re-
liably identify subgroups of women who have unprotected sexual activity
and could provide valuable exposure-based estimates of efficacy.
Amajor limitation of current HIV prevention trial design isthe lack of an accurate and sensitive means to measure ex-
posure to HIV.1,2 The evaluation of risk behavior using self-
reported condom use and frequency of coitus can be unreliable
because of miscommunication between interviewer and inter-
viewee, lack of understanding of the questions asked, reporting
behavior according to perceived expectations, inability to recall
experience, and blatant misreporting.3,4 In addition, self-report of
condom use frequency does not capture risk associated with im-
proper condom use or accidental condom breakage. Despite
greater than 80% reported condom use in VOICE, FEM-PrEP, and
the TDF2 study, pregnancy and HIV incidence rates remained
higher than expected.5Y7 A cross-sectional study of 910 women
in Zimbabwe found that only 52% of participants who tested
positive for prostate-specific antigen (PSA) in vaginal swabs
reported unprotected sex during the previous 2 days. Audio
computer-assisted self-interview technology did not generate sig-
nificantly different responses about unprotected intercourse com-
pared with face-to-face interview.8
The detection of semen could provide an unbiased mea-
sure of unprotected sex in participants of HIV prevention trials.
However, the limited sensitivity of the most commonly used
biomarker, PSA, makes it impractical for use in clinical studies
where swab collection could occur hours to weeks after inter-
course. Levels of PSA decline 10-fold by 3 hours postexposure
and are undetectable by 24 to 48 hours postexposure.9Y11 Rapid
stain identification of human semen that detects the presence of
semenogelin has also been used in trials to indicate that a woman
has been exposed to ejaculate in the previous 48 hours, but it is
10-fold less sensitive than quantitative polymerase chain reaction
(PCR) methods to detect Y chromosomal (Yc) DNA.12,13 Depite
heterogeneity in both initial deposit of Yc DNA and rate of
decline of Yc DNA signal, Yc has the advantage of detectability
up to 15 postcoital days from self-collected vaginal swabs without
impact from menses on the rate of decay.14,15 Y chromosome
DNA is not detected in women using condoms correctly, as dem-
onstrated by a study that showed that only 5 of 56 women had
positive Yc DNA results after condom use after a 14-day absti-
nence period, and the 5 detections were associated with receptive
oral sex and digital penetration.16,17
The detection of HIV in genital samples from HIV-negative
women could more directly assess HIV infection risk. In a study
of cervical dysplasia in US women, HIV-1 env and gag glyco-
proteins were identified in cervicovaginal lavage samples from
women who were confirmed to be HIV negative by serology.18
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However, partner HIV status was not known, and the linkage of
env and gag detection with future seroconversion was not veri-
fied. HIV-1 viral RNA and proviral HIV-1 DNA sequences can
be detected in seminal plasma and nonspermatazoal mononuclear
cells in HIV-infected men throughout successful long-term highly
active antiretroviral therapy, whereas plasma HIV-1 viral RNA
levels remain undetectable.19Y22 The detection of HIV DNA in
genital samples from HIV-negative women has not been studied
as a marker of HIV infection risk.
We therefore examined the frequency of Yc DNA and HIV
DNA detection in vaginal swabs collected in HIV seroconverters
(both preseroconversion and postseroconversion) and nonseroconverters
from the HPTN035 study, using highly sensitive quantitative PCR
assays with detection limits of a single copy.
MATERIALS AND METHODS
Study Population
HPTN 035 was a phase II/IIb safety and effectiveness study
of the vaginal microbicides BufferGel and 0.5% PRO2000/5 gel
for the prevention of HIV-1 infection in women, conducted from
February 2005 through September 2008 (NCT00074425). All par-
ticipants provided informed consent for swab collection and future
testing. The population demographic characteristics, protocol, and
trial results are described elsewhere.23 Starting in 2008, vaginal
swab specimens were collected from participants during each
quarterly pelvic examination by applying a Dacron swab to the
posterior fornix of the vagina until the tip was saturated with
fluid, then placing the swab in a cryovial containing 400 KL of
phosphate-buffered saline. The cryovials were stored at j80-C
at the sites and shipped to the MTN Network Laboratory after
the primary study results were available. The current study eval-
uated a case-control subset of swabs collected from women at sites
in Zimbabwe (Harare and Chitungwiza), South Africa (Hlabisa
and Durban), and Malawi (Blantyre and Lilongwe) at a 1:3 ratio
(seroconverters/nonseroconverters). Swabs from seroconverters
were collected both preseroconversion and postseroconversion.
Swabs from participants postseroconversion were collected a
median of 21 days after detection of seroconversion (range,
5Y124 days). Seroconverters were not taking antiretroviral therapy
at the time of swab collection. The operator performing the assays
was blinded to the subgroup to which the participant belonged.
Nucleic Acid Extraction
Swabs were processed to isolate the cell pellet as described
previously.24 Total nucleic acid was extracted by incubating the
vaginal swab cell pellet in 2 mg/mL Proteinase K solution (Applied
Biosystems) for 30 minutes at 55-C. Guanidinium isothiocyanate
(Sigma) and glycogen (Roche) were added to final concentrations
of 4.58 M and 0.47 mg/mL, respectively, and incubated at room
temperature for 30 minutes. Nucleic acids were precipitated by
centrifugation at 15,000  g in the presence of a nearly equal
volume of isopropanol. Nucleic acid pellets were washed repeti-
tively with 70% ethanol and air dried before suspending in 5 mM
Tris, pH 8. One third of the sample was used as template in the
Quantifiler Duo assay, one third was used for testing HIV-1 DNA,
and one third was stored.
Detection of HIV-1 DNA
HIV-1 DNAwas detected using a modified version of the
single copy assay with primers targeted to a conserved region in
the integrase gene (iSCA).25 Briefly, 10 KL of extracted DNA
was diluted with 20 KL of 5 mM Tris pH 8 and run in triplicate
in a reaction containing 1 Roche LightCyler 480 probes master
mix, 400 nM of primers iSCA-F (5¶-TTT GGA AAG GAC CAG
CCA A-3¶) and iSCA-r (5¶-CCT GCC ATC TGT TTT CCA-3¶)
and 200 nM Taqman probe (5¶-6FAM AAA GGT GAA GGG
GCA GTA GTA ATA C BHQ_1Y3¶). DNA was amplified at
95-C for 5 minutes followed by 45 cycles of 95-C for 15 seconds
and 60-C for 1 minute on a LightCycler 480 (Roche). This assay
can detect HIV-1 DNA at a single copy per well, as verified by
Poisson distribution statistics in limiting dilution experiments of
purified HIV-1 DNA target in mock swab cell pellets prepared
using A431 cells spiked with a known quantity of purified HIV-1
DNA and human semen. False-positive results were observed in
0 of 111 reactions using Tris buffer as a no template control. Each
sample was run in triplicate and considered ‘‘undetectable’’ if all
3 reactions had no amplification; ‘‘detected, quantifiable’’ if at
least 2 of 3 reactions had 1 or more copies detected per reaction;
and ‘‘detected, not quantifiable’’ if only 1 of 3 reactions had 1 or
more copies detected.
Detection of Yc DNA
Y chromosome and total human DNAwas detected using the
commercially available Quantifiler Duo kit (Applied Biosystems).
Reactions were prepared according to the manufacturer’s guide-
lines with the modification of increasing the total number of PCR
cycles from 40 to 55 to allow late amplification (935 cycles) to
reach the plateau phase of PCR, and to observe if any cases of
nonspecific amplification occurred after 40 cycles. Despite these
adjustments, all positive wells had cycle threshold values of 40
cycles or below, consistent with the kit manufacturer’s guidelines.
Wells with cycle threshold values of 40 to 41 that had exponential
amplification were included as positive only if the calculated copy
number was 1 copy or above. No cases of false amplification
between 41 and 55 cycles occurred. The assay can detect Yc DNA
at a single copy per well, as verified by Poisson distribution sta-
tistics in limiting dilution experiments of semen in mock swab
cell pellets. False-positive Yc DNA was observed in 0 of 135
reactions using Tris buffer as a no template control and 0 of 65
reactions using A431 female epithelial cell pellets as a negative
control. Positive detection using dilutions of semen was obtained
in 89 of 89 wells with a predicted copy number of 2 or higher.
Additional sensitivity and specificity information can be found in
the Quantifiler Duo user’s manual. Each test sample was run in
replicates of 5 and considered ‘‘undetectable’’ if all 5 reactions had
no amplification; ‘‘detected, quantifiable’’ if at least 3 of 5 re-
actions had 1 or more copies detected per reaction; and ‘‘detected,
not quantifiable’’ if only 1 or 2 reactions had at least 1 copy
detected per reaction. Total Human DNA, measured through the
RPPH1 target as part of the Quantifiler Duo kit, was used to cal-
culate approximate total cell numbers in each swab cell pellet and
quantified according to kit manufacturer’s instructions.
Behavioral Data Collection and Analysis
Participants were queried on gel and condom use during
the last coital act and during all coital acts in the last 7 days at
each quarterly visit, and data were collected by participant self-
report.23 Detected, but not quantifiable Yc DNA samples were
excluded from the analysis of Yc DNA detection with self-reported
condom use because of the inferior quality of these samples.
Statistical Analysis
SPSS Version 20 (IBM Corp.) was used for all analyses.
Conditional logistic regression was used to compare the odds of
being a seroconverter among those with detectable Yc DNA and
those with no detectable Yc DNA. The association between Yc
DNA detection (vs. no detection) and reported sexual activity
was assessed using generalized estimating equation models with a
binary link, robust errors, and independent correlation structure.
Biomarkers of HIV Exposure in Clinical Trials
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RESULTS
Swab Collection and Cell Recovery
In the HPTN 035 study, 3524 vaginal swab specimens were
collected from 2031 women from the African sites. A randomly
selected subset of 110 swabs from 65 women who remained HIV
negative throughout the study (controls) and 33 swabs from 18
women who seroconverted postenrollment (cases) were evaluated
for the presence of HIV and Yc DNA (Fig. 1). Of 33 swabs from
seroconverters, 10 were collected, whereas the women were still
HIV negative (before seroconversion) and 23 were collected after
the participant was confirmed as having seroconverted. Cell re-
covery from swabs as assessed through total human DNA detec-
tion was a median of 3.0  105 cells/swab (interquartile range,
1.4  105 to 6.1  106 cells/swab). Receiver operating charac-
teristic curve analysis demonstrated no minimal cell pellet size
requirement for the detection of Yc DNA. The minimum cell
number needed for HIV DNA recovery could not be determined
because of small sample size (data not shown).
HIV-1 DNA Detection
HIV-1 DNAwas only detected in 10 of 23 swabs collected
postseroconversion. Five had quantifiable HIV-1 DNA with a
median of 141 copies/sample and a range of 55 to 1593 copies/
sample from swabs that were collected postseroconversion, and
5 had HIV-1 DNA that was detected but not quantifiable (Table 1).
HIV-1 DNA could not be detected in the 10 samples collected
before seroconversion or in the 110 samples from women who
remained HIV-1 negative throughout the study.
Yc DNA Detection
All 143 swabs were evaluated for the presence of Yc DNA
as a measure of unprotected sexual activity. Y chromosome DNA
was detected in 62 of 143 (43%) swabs. Forty-four of 62 samples
had quantifiable Yc DNA, with a median of 425 copies/sample
and a range of 20 to 11926 copies/sample. Y chromosome DNA
was detected but not quantifiable in 18 of 62 (29%) samples
(Table 2). Using conditional logistic regression with serostatus as
the outcome, no significant differences in Yc DNA detection were
found between the HIV seroconverter cases (5/33 [15%]) and HIV
nonseroconverter controls (39/110 [35%]) in samples that had
quantifiable Yc DNA (P = 0.1). This difference remained non-
significant when samples collected before seroconversion were in-
cluded as cases (odds ratio [OR], 0.48; P = 0.3). There was no
correlation between Yc and HIV-1 DNA detection in the sample set.
Association of Yc DNA Detection With
Self-Reported Condom Use
Participant responses to frequency of coitus and condom
use were also collected at 126 of the 143 visits at which a swab
sample was collected. There were 27 (21%) reports of no vaginal
sex in the week before sample collection, 83 (66%) reports of
vaginal sex in the past week with 100% condom use, and 16 (13%)
Figure 1. Study design.
Penrose et al.
676 Sexually Transmitted Diseases & Volume 41, Number 11, November 2014
Copyright © 2014 by the American Sexually Transmitted Diseases Association. Unauthorized reproduction of this article is prohibited.
reports of vaginal sex in the past week with less than 100%
condom use. Excluding samples that were not quantifiable, the
proportion of participants with Yc DNA increased as reported
condom use decreased. Only 4 (15%) of 27 samples from par-
ticipants reporting no coitus had Yc DNA (median, 98 copies),
compared with 27 (33%) of 83 samples with Yc DNA (median,
518 copies) from participants reporting vaginal sex in the past
week with 100% condom use and 9 (56%) of 16 samples from
participants with Yc DNA (median, 568 copies) reporting vaginal
sex in the past week with less than 100% condom use. The pro-
portion of samples with Yc DNA was significantly higher (OR,
10.69; P = 0.003) among those participants with inconsistent
condom use compared with those reporting no coitus in the past
week (Table 3). Reporting of feminine hygiene practices did not
correlate with Yc DNA detection (data not shown).
DISCUSSION
The advent of new, highly sensitive quantitative PCR tech-
nologies for nucleic acid detection and quantification in genital
specimens enabled us to evaluate the feasibility of using HIVand
Yc DNA detection as a biomarker for risk behavior in HIV pre-
vention clinical trials. We quantified HIV and Yc DNA from the
same vaginal swab and stratified the results against behavioral
data on condom use from women both preseroconversion and
postseroconversion and from women who never seroconverted
in the trial period. The operator performing the assays was blinded
as to the subgroups to which the participants belonged.
Despite having an assay with sensitivity down to a single
copy of HIV-1 DNA per PCR reaction, we did not find evidence
of HIV-1 in specimens from seronegative women, including from
those women who eventually seroconverted. The inability to detect
seminal viral DNA (from an infected male partner) in a vaginal
swab sample could have been influenced by sample quality, timing
of swab sample collection from last coital act, and lack of frequent
exposure to HIV. Furthermore, CD4+ lymphocytes only comprise
2% of the total cell number in an average semen sample and only
0.1% of CD4+ T cells carry provirus in an HIV-infected individual.
The number of absolute CD4+ lymphocytes in semen can also
depend on the health of the individual and decrease dramatically
in viremic patients.26 Of note, the maximum number of Yc DNA
copies from any swab in our study was 1000 copies/well, with the
majority (134/143 [94%]) having Yc copies of 100 or less, meaning
that only a small fraction of semen was being detected. Because so
little of Yc DNA is being recovered from an ejaculate, it is very
unlikely that rare HIV-infected cells would have been detected.
We also did not observe a difference in frequency of Yc
DNA detection in seroconverters compared with nonseroconverters
(15% vs. 35%), and the number of copies of Yc detected did not
predict risk of seroconversion. Walsh et al.27 showed that there
was a significant difference in levels of PSA and sperm counts
with different types of risk exposures such as condom breakage,
but a similar analysis using Yc DNA has not been done. There are
several explanations for Yc DNA not predicting seroconversion
including variation in donor sperm count, variable time between
last coitus and sample collection, noncoital exposure (e.g. digital),
and limited sampling of seroconverters. Larger observations over
longer periods may reveal an association of Yc DNA exposure and
risk of HIVor other sexually transmitted infections.
Our data do provide further evidence that Yc chromosomal
DNA detection serves as a reliable biomarker to monitor sexual
activity.28 A significantly higher proportion of women (P = 0.003)
reporting unprotected sex in the past week had detectable Yc DNA
compared with women reporting no vaginal sex in past week. In-
terestingly, 33% of women reporting 100% condom use had de-
tectable Yc DNA, with copy numbers at similar levels to those
women reporting less than 100% condom use (518 vs. 568 copies),
suggesting that condom usage was overreported in this study or
that exposure occurred before the use of a condom. The behavioral
questionnaire was administered through face-to-face interviews,
which may contribute to inconsistent reporting particularly for
TABLE 1. Detection of HIV-1 DNA in a Subset of Vaginal Swabs From HPTN 035
HIV-1 DNA*
Seronegative†
(n = 110), n (%)
Preseroconversion‡
(n = 10), n (%)
Postseroconversion (n = 23)
n (%) Median (range) copies/sample
Undetectable 110 (100) 10 (100) 13 (50) V
Detected, quantifiable 0 0 5 (25) 141 (55Y1593)
Detected, not quantifiable 0 0 5 (25) V
*Each sample was run in triplicate and considered ‘‘undetectable’’ if all 3 reactions had no amplification; ‘‘detected, quantifiable’’ if at least 2/3
reactions had 1 or more copies detected per reaction; and ‘‘detected, not quantifiable’’ if only 1 of 3 reactions had 1 or more copies detected.
†Swab sample collected from participant who remained seronegative at study termination.
‡Swab sample collected from participant who was seronegative at time of sample collection, but seropositive at study termination.
TABLE 2. Detection of Yc DNA in a subset of vaginal swabs from HPTN 035
Yc DNA*
Seronegative† (n = 110) Seropositive‡ (n = 33)
n (%) Median (range) copies/sample n (%) Median (range) copies/sample
Undetectable 62 (56) V 19 (58) V
Detected, quantifiable 39 (35) 413 (16Y7003) 5 (15) 626 (74Y11926)
Detected, not quantifiable 9 (8) V 9 (27) V
*Each sample was run in replicates of 5 and considered ‘‘undetectable’’ if all 5 reactions had no amplification; ‘‘detected, quantifiable’’ if at least
3 of 5 reactions had 1 or more copies detected per reaction; and ‘‘detected, not quantifiable’’ if only 1 or 2 reactions had at least 1 copy detected
per reaction.
†Swab sample collected from participant who remained seronegative at study termination.
‡Swab sample collected from participant who was seropositive at study termination. Ten samples were collected preseroconversion, and 23 samples
were collected postseroconversion.
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sensitive topics.29 Our data show promise for the use of Yc DNA
as an objective measure for condom use. Further study is needed
to determine if level of risk or type of risk behavior can be cor-
related with number of Yc copies detected.
One limitation of this study is that testing for HIVand Yc
DNA was done retrospectively on stored swabs from quarterly
sampling, where timing of swab collection after coitus and the
HIV infection status of the male partner was not known. Testing
a larger number of preseroconversion swabs or swabs from
serodiscordant couples could provide further insight into the fea-
sibility of using HIV or Yc DNA as a biomarker. Self-collected
samples could provide the best timing for detecting HIV expo-
sure, but would rely on the ability and willingness of participants
to collect high-quality samples. More frequent sample collection
could provide risk information to statisticians for refined secondary
analysis of clinical trial data in populations of highest risk. Mod-
ifying the assay for HIV detection to include HIV-1 RNA or total
nucleic acid detection may improve sensitivity.
In summary, we demonstrated that by using highly sensi-
tive quantitative PCR assays, Yc DNA and total HIV-1 DNA can
be detected down to a single copy in vaginal swab samples. Y
chromosome DNA detection is more frequent among women
reporting less than 100% condom use with coitus but can also
be detected in a third of women reporting 100% condom usage.
These results suggest that Yc DNA detection in vaginal fluids could
refine assessments of HIV risk and efficacy of preventive strategies.
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